ProMIS Neurosciences, Inc. (PMN)
- Previous Close
1.9700 - Open
1.9200 - Bid --
- Ask 2.3500 x 1700
- Day's Range
1.9200 - 2.3400 - 52 Week Range
0.9500 - 8.9500 - Volume
5,833 - Avg. Volume
21,514 - Market Cap (intraday)
36.974M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0700 - Earnings Date Mar 6, 2024 - Mar 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.75
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
www.promisneurosciences.comRecent News: PMN
Performance Overview: PMN
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PMN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PMN
Valuation Measures
Market Cap
37.92M
Enterprise Value
28.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.10
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.17
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-81.92%
Return on Equity (ttm)
-1,098.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.21M
Diluted EPS (ttm)
-1.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
12.64M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.3M
Research Analysis: PMN
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell